BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29880615)

  • 1. Mass cytometry of Hodgkin lymphoma reveals a CD4
    Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
    Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
    Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Blood; 2017 Nov; 130(21):2265-2270. PubMed ID: 29167175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
    Liu WR; Shipp MA
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
    Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
    Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of CD4+CD25 +FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil.
    Assis MC; Campos AH; Oliveira JS; Soares FA; Silva JM; Silva PB; Penna AD; Souza EM; Baiocchi OC
    Med Oncol; 2012 Dec; 29(5):3614-9. PubMed ID: 22791223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
    Nagpal P; Descalzi-Montoya DB; Lodhi N
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
    Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
    Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
    Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
    Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
    Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.
    Wienand K; Chapuy B; Stewart C; Dunford AJ; Wu D; Kim J; Kamburov A; Wood TR; Cader FZ; Ducar MD; Thorner AR; Nag A; Heubeck AT; Buonopane MJ; Redd RA; Bojarczuk K; Lawton LN; Armand P; Rodig SJ; Fromm JR; Getz G; Shipp MA
    Blood Adv; 2019 Dec; 3(23):4065-4080. PubMed ID: 31816062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
    Ferrarini I; Rigo A; Zamò A; Vinante F
    Leuk Lymphoma; 2019 Dec; 60(14):3395-3405. PubMed ID: 31304817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses.
    Chen X; Yu J; Venkataraman G; Smith SM; Chen M; Cooper A; Tumuluru S; Brody JD; Godfrey J; Kline J
    Cancer Immunol Res; 2024 Mar; 12(3):296-307. PubMed ID: 38240659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells.
    Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S
    Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
    Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.